Taxol is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Taxol is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called paclitaxel.
Scientists have uncovered critical new details about the mechanisms that modulate the response of ovarian cancer cells to chemotherapy.
With the discovery of suitable molecular targets - cellular molecules along pathways crucial for sustaining the life of cancer cells - comes the perplexing dilemma of where to find the next therapeutics that will bind to and disable those targets.
The breast cancer drugs called taxanes, which include Taxol (paclitaxel) and Taxotere (docetaxel), increase survival rates when used as part of chemotherapy following surgery for cancers that have not spread, according to a new review of the research.
Merging technological innovations and new knowledge about basic cancer biology, cancer researchers now target specific molecules involved in critical chemical pathways of cancerous cells.
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Microorganisms may soon be efficiently and inexpensively producing novel pharmaceutical compounds, such as flavonoids, that fight aging, cancer or obesity, as well as high-value chemicals, as the result of research being conducted by University at Buffalo researchers.
Rice University chemists have discovered a way to load dozens of molecules of the anti-cancer drug paclitaxel onto tiny gold spheres. The result is a tiny ball, many times smaller than a living cell that literally bristles with the drug.
Imagine the day when a routine visit to the family doctor includes a simple blood test to predict the risk for developing Alzheimer's disease (AD).
Scientists have long thought that microtubules, part of the microscopic scaffolding that the cell uses to move things around in order to hold its shape and divide, originated from a tiny structure near the nucleus, called the centrosome.
Researchers at UCLA have successfully manipulated nanomaterials to create a new drug-delivery system that promises to solve the challenge of the poor water solubility of today's most promising anticancer drugs and thereby increase their effectiveness.
Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology (ASCO) Annual Meeting.
An updated analysis of two large randomized clinical trials has found that breast cancer patients who received the monoclonal antibody trastuzumab (Herceptin) along with chemotherapy are living longer and with less risk of recurrent disease, compared to patients treated with chemotherapy alone.
Statistics show lung cancer is the leading cause of cancer death in African-Americans, with 21,550 new cases expected to be diagnosed and 16,700 deaths expected this year.
Integrating the use of drugs targeted to specific cancer proteins into current chemotherapy regimens to improve the efficacy of systemic treatment is an important clinical goal at Fox Chase Cancer Center.
Using a technology that can quickly screen all 20,000-plus human genes for biological activity, scientists have isolated 87 genes that seem to affect how sensitive human cancer cells are to certain chemotherapy drugs.
Cancer researchers at Georgetown University Medical Center have taken a step towards understanding how and why a widely used chemotherapy drug works in patients with breast cancer.
Researchers in the United States appear to have almost inadvertently stumbled across what could be a new cancer treatment.
The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.
Combining a monoclonal antibody known to target melanoma tumors with multiple C60 buckyballs, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have developed a new way to deliver multiple drugs simultaneously to tumors.
It may be possible to protect the testes of cancer patients against the loss of fertility caused by chemotherapy.